Gastro-oesophageal reflux disease in Asia - Birth of a 'new' disease?

被引:12
作者
Cheung, Ting K. [1 ]
Wong, Benjamin C. Y. [1 ]
Lam, Shiu K. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.2165/00003495-200868040-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gastro-oesophageal reflux disease (GORD) is one of the most common gastrointestinal diseases in the Western world and imposes a heavy burden on society. Although its prevalence in Asia is much lower, there is evidence that this is rapidly rising in Asia. The reported population prevalence of GORD in Eastern Asia ranges from 2.5% to 6.7% for at least weekly symptoms of heartburn and/or acid regurgitation. In general, Asians tend to have a milder spectrum of the disease. Most Asian patients have non-erosive GORD; erosive oesophagitis is less commonly seen than in the Western population. Complicated GORD, such as oesophageal stricture and Barrett's oesophagus, is seldom encountered. The mechanisms of GORD may be different in the Chinese population compared with the Western population. Chest pain is the most predominant extra-cesophageal manifestation of GORD in China, whereas an association with asthma has been shown in Japanese patients. The prevalence of GORD appears to be increasing and possible factors for GORD in Asian populations include Helicobacter pylori infection, obesity and increasing dietary fat intake. The adoption of a Western lifestyle in many developing Asian countries may account for the increasing prevalence of GORD. Proton pump inhibitors remain the most effective medical treatment for GORD. GORD will undoubtedly be a great challenge to clinicians both in primary care and in gastroenterology practice in the Asia-Pacific region in the coming years.
引用
收藏
页码:399 / 406
页数:8
相关论文
共 87 条
[11]   Rabeprazole in treatment of acid peptic diseases - Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD) [J].
Cloud, ML ;
Enas, N ;
Humphries, TJ ;
Bassion, S .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (05) :993-1000
[12]   DOUBLE-BLIND COMPARISON OF OMEPRAZOLE (40 MG OD) VERSUS CIMETIDINE (400 MG QD) IN THE TREATMENT OF SYMPTOMATIC EROSIVE REFLUX ESOPHAGITIS, ASSESSED ENDOSCOPICALLY, HISTOLOGICALLY AND BY 24 H PH MONITORING [J].
DEHN, TCB ;
SHEPHERD, HA ;
COLINJONES, D ;
KETTLEWELL, MGW ;
CARROLL, NJH .
GUT, 1990, 31 (05) :509-513
[13]   MECHANISM OF GASTROESOPHAGEAL REFLUX IN RECUMBENT ASYMPTOMATIC HUMAN-SUBJECTS [J].
DENT, J ;
DODDS, WJ ;
FRIEDMAN, RH ;
SEKIGUCHI, T ;
HOGAN, WJ ;
ARNDORFER, RC ;
PETRIE, DJ .
JOURNAL OF CLINICAL INVESTIGATION, 1980, 65 (02) :256-267
[14]  
DENT J, 1999, GUT, V44, P2
[15]   Updated guidelines for the diagnosis and treatment of Gastroesophageal reflux disease [J].
DeVault, KR ;
Castell, DO .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :190-200
[16]   MECHANISMS OF GASTRO-ESOPHAGEAL REFLUX IN PATIENTS WITH REFLUX ESOPHAGITIS [J].
DODDS, WJ ;
DENT, J ;
HOGAN, WJ ;
HELM, JF ;
HAUSER, R ;
PATEL, GK ;
EGIDE, MS .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (25) :1547-1552
[17]   A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis [J].
Earnest, DL ;
Dorsch, E ;
Jones, J ;
Jennings, DE ;
Greski-Rose, PA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (02) :238-243
[18]   Extraesophageal gastroesophageal reflux disease - Presentations and approach to treatment [J].
Fennerty, MB .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (04) :861-+
[19]   National trends in utilization and outcomes of antireflux surgery [J].
Finlayson, SRG ;
Laycock, WS ;
Birkmeyer, JD .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2003, 17 (06) :864-867
[20]   Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease [J].
Fock, KM ;
Talley, N ;
Hunt, R ;
Fass, R ;
Nandurkar, S ;
Lam, SK ;
Goh, KL ;
Sollano, J .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (04) :357-367